Pancreatic Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 91 expanded access programs, clinical trials, and compassionate use pathways listed for Pancreatic Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with pancreatic cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 29 programs are currently active or recruiting, with the remaining 62 in other lifecycle stages. Sponsors actively running programs in this area include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Revolution Medicines, Inc., National Cancer Institute (NCI), Massachusetts General Hospital, M.D. Anderson Cancer Center, and others.
By recruiting status
Snapshot of where every Pancreatic Cancer program currently sits in its lifecycle.
- Active / Recruiting29
- Inactive62
Top sponsors
Organisations running the most Pancreatic Cancer programs in the directory.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins6 programs
- Revolution Medicines, Inc.5 programs
- National Cancer Institute (NCI)4 programs
- Massachusetts General Hospital3 programs
- M.D. Anderson Cancer Center2 programs
- Medical College of Wisconsin2 programs
- Nuvation Bio Inc.2 programs
- A2 Biotherapeutics Inc.1 program
- Actuate Therapeutics Inc.1 program
- Agenus Inc.1 program
Pancreatic Cancer programs (91)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 for Patients with Advanced Cancers — Actuate Therapeutics Inc.
- Study on ODM-212 for Adults with Advanced Solid Tumors — Orion Corporation, Orion Pharma
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Study on DM002 for Patients with Advanced Solid Tumors — Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- Study on the Effectiveness and Safety of Setidegrasib with Chemotherapy for Pancreatic Cancer — Astellas Pharma Global Development, Inc.
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on AMXI-5001 for Treating Advanced Cancers — AtlasMedx, Incorporated
- Study on ANO31905 with Chemotherapy for Advanced Pancreatic Cancer with CLDN18.2 Marker — Anova Innovation Limited
- Study on Atebimetinib and Modified Chemotherapy for First-Line Treatment of Metastatic Pancreatic Cancer — Immuneering Corporation
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Boosting GVAX Pancreas Vaccine with or without Cyclophosphamide for Pancreatic Cancer Patients — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Claudin18.2 CAR-T Therapy for Patients with Advanced Gastric, Pancreatic, or Other Digestive Cancers — CARsgen Therapeutics Co., Ltd.
- Study on Combining Immunotherapy with Standard Chemotherapy for Advanced Pancreatic Cancer — ImmunityBio, Inc.
- Study Comparing Two Vaccine Combinations with Immunotherapy for Treatable Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on ENB003 and Pembrolizumab for Treating Solid Tumors — ENB Therapeutics, Inc
- Expanded Access Program for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer — Revolution Medicines, Inc.
- Expanded Access Program for SL-28 in Treating Advanced Solid Tumors — Second Life Therapeutics
- Study on Losartan and Nivolumab Combined with FOLFIRINOX and Radiation for Localized Pancreatic Cancer — Massachusetts General Hospital
- Study on DZ-002 Maintenance Therapy for Metastatic Pancreatic Cancer — Hoag Memorial Hospital Presbyterian
- Study on NC410 and FOLFIRINOX with Nivolumab and Possibly Ipilimumab for Untreated Metastatic Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Nivolumab, Ipilimumab, and Radiation for Microsatellite Stable Pancreatic Cancer — Massachusetts General Hospital
- Study on Onvansertib and NALIRIFOX for First-Line Treatment of Advanced Pancreatic Cancer — University of Kansas Medical Center
- Study on BHB810 for Advanced Stomach and Gastroesophageal Cancer — BigHat Biosciences, Inc.
- Study on Anti-CEACAM5 ADC M9140 for Advanced Solid Tumors (PROCEADE PanTumor) — EMD Serono Research & Development Institute, Inc.
- Study on Daraxonrasib for Patients with Surgically Removed Pancreatic Cancer — Revolution Medicines, Inc.
- Study on Daraxonrasib and Daraxonrasib with Chemotherapy as First Treatment for Metastatic Pancreatic Cancer — Revolution Medicines, Inc.
- Study on Zoldonrasib with Chemotherapy vs. Placebo with Chemotherapy for First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Cancer — Revolution Medicines, Inc.
- Study on VMD-928 Alone and with Pembrolizumab for Treating Solid Tumors or Lymphoma with High TrkA Levels — VM Oncology, LLC
- Study on ZN-c3 and Gemcitabine for Pancreatic Cancer — Brandon Huffman
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on Tislelizumab and SX-682 for Treatable Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Phase II Study of Immunotherapy for Advanced Gastrointestinal Cancers with KRAS or TP53 Mutations — National Cancer Institute (NCI)
- Phase III Study of Second-Line Treatment for Advanced Pancreatic Cancer: Comparing Chemotherapy and Supportive Care — CONKO-Studiengruppe
- Study on FMC-376 for Patients with KRAS G12C Mutated Advanced Solid Tumors — Frontier Medicines Corporation
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Using Genetically Modified Immune Cells to Treat Metastatic Gastrointestinal Cancers — Intima Bioscience, Inc.
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on TAK-500 With or Without Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors — Takeda
- Study on the Safety and Tolerability of TST001 for Advanced or Metastatic Solid Tumors — Suzhou Transcenta Therapeutics Co., Ltd.
- Study on Using Gemcitabine and Capecitabine Chemotherapy After Surgery for Pancreatic Cancer — Rutgers, The State University of New Jersey
- Study on Using Genetically Modified White Blood Cells to Treat Cancers with CD70 Marker — National Cancer Institute (NCI)
- Using Modified White Blood Cells to Target G12D Mutated RAS in Cancer Patients with HLA-A*11:01 — National Cancer Institute (NCI)
- Study on Using Genetically Modified White Blood Cells to Treat Cancers with a Specific KRAS Mutation in HLA-A*11:01 Patients — National Cancer Institute (NCI)
- Study on Using Tumor Infiltrating Lymphocytes for Treating Advanced Solid Cancers — Udai Kammula
- Study on AGEN1423 and Botensilimab with or without Chemotherapy for Advanced Pancreatic Cancer — Bruno Bockorny
- Study on Ampligen Compared to No Treatment After FOLFIRINOX in Patients with Locally Advanced Pancreatic Cancer — AIM ImmunoTech Inc.
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Study on Atezolizumab and Cabozantinib for Patients with Advanced, Hard-to-Treat Pancreatic Cancer — University of Arizona
- BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast — Aveni Foundation
- Study on BOLD-100 with FOLFOX for Treating Advanced Solid Tumors — Bold Therapeutics, Inc.
- Study on Combination Treatment with Chemokine Inhibitor, Immunotherapy, and Chemotherapy for Pancreatic Cancer — Gulam Manji
- Study on Low Dose G-FLIP and Mitomycin C for Advanced Pancreatic Cancer — Hirschfeld Oncology
- Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma — SOTIO Biotech a.s.
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
- Expanded Access for Treating Cancers with RET Activation — Eli Lilly and Company
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on the Feasibility of Using the LUM Imaging System to Detect Gastrointestinal Cancers — Lumicell, Inc.
- First in Human Study of Anti-PAUF Monoclonal Antibody PBP1510 for Pancreatic Cancer — Prestige Biopharma Limited
- Feasibility Study on Using a New Radiation Device for Treating Borderline Resectable Pancreatic Cancer — CivaTech Oncology
- LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer — Lokon Pharma AB
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Study on Modulating Gut Microbiome with Pembrolizumab After Chemotherapy in Resectable Pancreatic Cancer — Icahn School of Medicine at Mount Sinai
- Study on Niraparib for Treating Pancreatic Cancer — Dana-Farber Cancer Institute
- Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer — Massachusetts General Hospital
- Study on NUV-868 Alone and with Olaparib or Enzalutamide for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Pancreatic Cancer Study on Adaptive Chemotherapy Before Surgery — Medical College of Wisconsin
- Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on TROP2 CAR-Engineered Cord Blood-Derived NK Cells and Belzutifan for Pancreatic Cancer — M.D. Anderson Cancer Center
- Phase 2 Study of Futibatinib with PD-1 Antibody Therapy for Solid Tumors — Taiho Oncology, Inc.
- Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for First-Line Treatment in Patients with Metastatic Pancreatic Cancer — Trishula Therapeutics, Inc.
- Phase 3 Study of RMC-6236 for Patients with Previously Treated Metastatic Pancreatic Cancer — Revolution Medicines, Inc.
- Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma — Yale University
- Study on Immunotherapy Before and After Surgery for Patients with Resectable Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Proton Radiation for Pancreatic Cancer That Cannot Be Removed by Surgery — Proton Collaborative Group
- Study on Personalized Chemotherapy for Pancreatic Cancer Using RNA Profiling — Medical College of Wisconsin
- Study on the Safety and Effectiveness of NUV-1511 for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 as Additional Treatment After Surgery for Pancreatic Cancer — BioNTech SE
- Study on Combining Stereotactic Body Radiotherapy with FAK and RAF/MEK Inhibitors for Advanced Pancreatic Cancer — Washington University School of Medicine
- Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer — Wake Forest University Health Sciences
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study on EGFRBi Armed Fresh White Blood Cells for Advanced or Inoperable Pancreatic Cancer — University of Virginia
- Study on TNG260 and an Anti-PD Antibody for Solid Tumors with STK11 Mutation — Tango Therapeutics, Inc.
- Study on TROP2 CAR-Engineered IL15-Transduced Cord Blood NK Cells for Treating Resistant Ovarian, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer — M.D. Anderson Cancer Center
- Study on Switch Maintenance Therapy for Pancreatic Cancer — James Cleary, MD, PhD
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Panatic Cancer — Alliance for Clinical Trials in Oncology
- Study on Radiotherapy Combined with TTI-101 for Patients with Borderline Resectable Pancreatic Cancer — University of Colorado, Denver
- Study on XB2001 with ONIVYDE and 5-FU/LV for Advanced Pancreatic Cancer — XBiotech, Inc.
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Pancreatic Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.